¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2022³â ´ëÇѼҾư¨¿°ÇÐȸ Ãá°èÇмú´ëȸ(°¨¿°°ü¸®¿¬¼ö±³À° 5½Ã°£ ÀÎÁ¤) : 2022-05-28

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
2022³â ´ëÇѼҾư¨¿°ÇÐȸ Ãá°èÇмú´ëȸ(°¨¿°°ü¸®¿¬¼ö±³À° 5½Ã°£ ÀÎÁ¤) : 2022-05-28
±³À°ÀÏÀÚ : 2022-05-28
±³À°Àå¼Ò : ÇѾç´ëÇб³ HIT ´ëȸÀǽǠ 
±³À°ÁÖÁ¦ : 2022³â ´ëÇѼҾư¨¿°ÇÐȸ Ãá°èÇмú´ëȸ(°¨¿°°ü¸®¿¬¼ö±³À° 5½Ã°£ ÀÎÁ¤)
ÁÖÃÖ±â°ü : ´ëÇѼҾư¨¿°ÇÐȸ
´ã´çÀÚ : ±è¿µ¶õ
¿¬¶ôó : 02-3478-1668  
À̸ÞÀÏ : kspid@kspid.or.kr      
±³À°Á¾·ù : ¼Ò¾Æû¼Ò³â°ú      
Âü¼®¿¹»óÀοø : 300¸í
Èñ¸ÁÆòÁ¡ : 5Á¡   (ÀÏ¹Ý 4Á¡ / Çʼö 1Á¡)  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 5 ½Ã°£ 0ºÐ  
¼¼ºÎ¼ö°­·á : 60,000¿ø      
ºñ°í È¸¿ø: 40,000¿øºñȸ¿ø: 60,000¿øÀü°øÀÇ ¹× Çлý: 10,000¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 05-28 ÇѾç´ëÇб³ HIT ´ëȸÀǽǠ10:00~10:30 Recent advances in prevention of RSV in young infants  À±±â¿í(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 05-28 ÇѾç´ëÇб³ HIT ´ëȸÀǽǠ10:30~11:00 Advances in development of Influenza vaccines  ±èÀ±°æ(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 05-28 ÇѾç´ëÇб³ HIT ´ëȸÀǽǠ11:00~11:30 Prevention strategies for CMV infection  ÀÌÁø¾Æ(¿ï»êÀÇ´ë) 
±âŸ 05-28 ÇѾç´ëÇб³ HIT ´ëȸÀǽǠ11:30~12:00 ÃÑȸ  () 
½Ä»ç 05-28 ÇѾç´ëÇб³ HIT ´ëȸÀǽǠ12:00~13:00 Á߽Ġ () 
±³À°½Ã°£ 05-28 ÇѾç´ëÇб³ HIT ´ëȸÀǽǠ13:00~13:40 Past, present, and future of mRNA vaccines  Á¶´ë¼±/TBD(ÀüºÏÀÇ´ë/Moderna) 
±³À°½Ã°£ 05-28 ÇѾç´ëÇб³ HIT ´ëȸÀǽǠ13:40~14:20 COVID-19 in children and pregnant women in Japan  Kensuke Shoji(National Center for Child Health and Development) 
±³À°½Ã°£ 05-28 ÇѾç´ëÇб³ HIT ´ëȸÀǽǠ14:20~15:00 Clinical features of COVID-19 in children in Korea  Çѹ̼±(¼­¿ïÀÇ´ë) 
È޽Ġ05-28 ÇѾç´ëÇб³ HIT ´ëȸÀǽǠ15:00~15:20 È޽Ġ () 
±³À°½Ã°£ 05-28 ÇѾç´ëÇб³ HIT ´ëȸÀǽǠ15:20~15:50 Issues on COVID-19 vaccines in children: effectiveness, safety and goals  ÃÖ¿µÁØ(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 05-28 ÇѾç´ëÇб³ HIT ´ëȸÀǽǠ15:50~16:20 Surveillance during the COVID-19 pandemic: modeling and monitoring  Á¤ÀçÈÆ(°¡ÃµÀÇ´ë) 
±³À°½Ã°£ 05-28 ÇѾç´ëÇб³ HIT ´ëȸÀǽǠ16:20~16:50 Reflecting on infection control measures in COVID-19: what was necessary and what was not?  Á¶Çý°æ(°¡ÃµÀÇ´ë) 
±âŸ 05-28 ÇѾç´ëÇб³ HIT ´ëȸÀǽǠ16:50~17:00 Çмú³í¹®»ó ¹× PIV ¿ì¼ö ½É»çÀ§¿ø»ó ¼ö»ó  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2022³â ´ëÇѼҾư¨¿°ÇÐȸ Ãá°èÇмú´ëȸ(°¨¿°°ü¸®¿¬¼ö±³À° 5½Ã°£ ÀÎÁ¤) : 2022-05-28""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2022³â Á¦ 82Â÷ ´ëÇÑ»ý½ÄÀÇÇÐȸ Ãá°èÇмú´ëȸ : 2022-05-29
´ÙÀ½±Û 2022 Çѱ¹¸ðÀÚº¸°ÇÇÐȸ Á¦50ȸ Ãá°è¿¬¼ö°­Á : 2022-05-25
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20790 °æ±â ´ëÇÑÇǺΰúÇÐȸ Á¦52Â÷ ÀÎõºÎõÁöºÎȸ ÇмúÁý´ãȸ : 2024-06-15 0 0 2024-05-27
20789 ¼­¿ï 2024³â ´ëÇѽŰæ±ÙÀ°ÁúȯÇÐȸ ¿¬¼ö°­Á : 2024-06-15 0 2 2024-05-27
20788 Á¦ÁÖ ´ëÇѳ»ºÐºñÇÐȸ Á¦22ȸ ºÐ°úÀü¹®ÀÇ ¿¬¼ö°­Á : 2024-06-15 0 2 2024-05-27
20787 Ãæ³² (¿Â¶óÀÎ)2024³âµµ Ãæû³²µµÀÇ»çȸ Ãá°èÇмú´ëȸ : 2024-06-15 0 2 2024-05-27
20786 ºÎ»ê KSMO ºÎ»ê¿ï»ê°æ³²/´ë±¸°æºÏÁöȸ °øµ¿ ½ÉÆ÷Áö¾ö : 2024-06-14 0 2 2024-05-27
20785 ¼­¿ï 2024³â ´ëÇѺҾÈÀÇÇÐȸ Ãá°èÇмú´ëȸ (´Ù½Ã, °Ü¿ï³ª¹«¿¡¼­ º½ ³ª¹«¿¡·Î From Traditional approaches to Innovation in Psychiatry) : 2024-06-14 0 2 2024-05-27
20784 ¼­¿ï ´ëÇÑ°áÇÙÇùȸ 2024³â °áÇÙ°ü¸®±³À° 1±â(2ÀÏÂ÷) : 2024-06-14 0 3 2024-05-27
20783 ¼­¿ï Á¦14Â÷ Çѱ¹ÃÖ¼Òħ½ÀÃéÀå¼ö¼ú¿¬±¸È¸ : 2024-06-14 0 0 2024-05-27
20782 ´ëÀü 2024 Á¦40ȸ ´ëÇѼҾƿܰúÇÐȸ Ãá°èÇмú´ëȸ ¹× 40Áֳ⠱â³äÇà»ç (2ÀÏÂ÷) : 2024-06-14 0 2 2024-05-27
20781 ´ë±¸ Ä¥°î°æºÏ´ëÇб³º´¿ø RARE DISEASE SYMPOSIUM 2024 : 2024-06-14 0 0 2024-05-27
20780 ºÎ»ê 2024 ´ëÇѽŰæ¿Ü°úÇÐȸ ºÎ»ê¿ï»ê°æ³²Áöȸ Á¦2Â÷ Á¤±âÇмú´ëȸ : 2024-06-14 0 2 2024-05-27
20779 ¼­¿ï 2024 ´ëÇÑÀÇÇÐȸ Çмú´ëȸ : 2024-06-14 0 2 2024-05-27
20778 ¼­¿ï ´ëÇÑÁø´ÜÀ¯ÀüÇÐȸ 2024³â Á¦19Â÷ Çмú´ëȸ (2ÀÏÂ÷) : 2024-06-14 0 0 2024-05-27
20777 ¼­¿ï 2024 ´ëÇÑÈ­»óÇÐȸ Çмú´ëȸ(2ÀÏÂ÷) : 2024-06-14 0 2 2024-05-27
20776 ºÎ»ê 2024³â Çѱ¹°£´ãÃé¿Ü°úÇÐȸ ºÎ¿ï°æÁöȸ °£ÀÌ½Ä ½ÉÆ÷Áö¾ö : 2024-06-14 0 2 2024-05-27
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷